• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Repeated stimulation treatment can restore movement in paralysed muscle

, 26 August 2020/in E-News /by 3wmedia

Conducted at the BioMag laboratory at the Helsinki University Hospital, a new patient study could open a new opportunity to rehabilitate patients with spinal cord damage. Dr Anastasia Shulga, a medical doctor specialising in neurology, led a study in which two patients with spinal cord injuries received a form of treatment that combined transcranial magnetic stimulation with simultaneous peripheral nerve stimulation given repeatedly for nearly six months. This was the first time that attempts were made to rehabilitate patients paralysed as a result of a spinal cord injury through long-term stimulation treatment of this type.

Both patients who participated in the study had spinal cord injuries caused by trauma. One patient was paraplegic, paralysed from the knees down, and the other was tetraplegic, with some voluntary movement of the hands but no capacity to grasp. Both patients had been injured more than two years ago and had received conventional rehabilitation treatments throughout their recovery, and continued to do so during the stimulation treatment.

After approximately six months of the stimulation treatment, the paraplegic patient could bend both ankles, and the tetraplegic could grasp an object.

‘We observed strengthened neural connections and partial restoration of movement to muscles which the patients were previously entirely unable to use,’ explains Anastasia Shulga.

The movement restored during the treatment was still present a month after the stimulation treatment had ended. One of the patients is participating in a further study in which stimulation is given more extensively and for an even longer period.

Dr. Jyrki Makela, head of the BioMag laboratory, points out that rehabilitation of patients with chronic spinal cord injuries is highly challenging, and new treatment methods are sorely needed:

‘This is a case study with two patients only, but we think the results are promising. Further study is needed to confirm whether long-term paired associative stimulation can be used in rehabilitation after spinal cord injury by itself and, possibly, in combination with other therapeutic strategies.’

Helsinki University www.helsinki.fi/en/news/repeated-stimulation-treatment-can-restore-movement-to-paralysed-muscles

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:22Repeated stimulation treatment can restore movement in paralysed muscle

Ultrasound devices market to reach Euro 9.32 million, globally, by 2022

, 26 August 2020/in E-News /by 3wmedia

The radiology/general imaging segment accounted for the major share of 30percent of the overall ultrasound market in 2015. This is primarily due to the wide adoption of ultrasound devices in the diagnosis of rising number of abdominal diseases. Urology has emerged as the fastest growing segment, registering a CAGR of 11.3percent during the forecast period, due to the growing incidences of urinary tract infections coupled with the rapidly aging patient population.
A new report published by Allied Market Research, titled, ‘Ultrasound Devices Market – Global Opportunity Analysis and Industry Forecast, 2014 – 2022’, projects that the global ultrasound market would reach $10,476 million ( Euro 9.32 milliion) by 2022. Diagnostic ultrasound system would continue to be the highest revenue-generating segment throughout the forecast period. Europe accounted for almost one-third of the market share in 2015, and is expected to dominate the overall market during the study period.
The major factors boosting the market growth include technological advancements (such as advent of 3D and 4D ultrasound that provides detailed information about a known abnormality from different angles), rising incidence of chronic diseases, and increasing geriatric population worldwide. The rising number of application areas of ultrasound coupled with increasing adoption of ultrasound systems in the obstetrics and gynecology field, is set to boost the growth of the ultrasound market worldwide. Cost effectiveness, safety, high accessibility, and clinical value in preliminary diagnosis are strengthening the technology’s value proposition in technological advancements in the ultrasound market. In addition, increase in number of diagnostic imaging procedures, and rising awareness for early diagnosis of clinical disorders are anticipated to further drive the demand for ultrasound devices. However, dearth of skilled and experienced sonographers and technological limitations of ultrasound systems are some of the factors restricting the market growth.
Diagnostic ultrasound devices such as 2D ultrasound, 3D & 4D ultrasound, and Doppler devices have given rise to new applications (such as biopsies and image-guiding interventions) across different clinical specialities. The growing demand for both ultra-portable and portable diagnostic ultrasound systems in diagnostic and image guidance area at points-of-care have further boosted the market growth. The advent of portability in ultrasound has built a strong path for the increased demand of these devices for point-of-care applications such as emergency medicine, anesthesiology, musculoskeletal, and critical care medicine. The trolley/cart-based ultrasound devices segment accounted for the major market share of the total ultrasound market in 2015, whereas, the compact/handheld ultrasound devices segment is expected to grow at a higher CAGR during the forecast period

Allied Market Research http://tinyurl.com/hgmpxfc

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:09Ultrasound devices market to reach Euro 9.32 million, globally, by 2022

Imaging assessment of prosthetic heart valves

, 26 August 2020/in E-News /by 3wmedia

The first recommendations on multimodality imaging assessment of prosthetic heart valves have been published.
The novel document was produced by the European Association of Cardiovascular Imaging (EACVI), a registered branch of the European Society of Cardiology (ESC). They are endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging.
‘Prosthetic heart valves are the best treatment for the majority of patients with severe symptomatic valvular heart disease,’ said first author Professor Patrizio Lancellotti. ‘Heart valve disease is one of the most common types of cardiovascular disease and affects around 3-6% of the population over 65 years.’
Heart valve replacement is performed using mechanical or biological prostheses. It is estimated that by 2050, some 850 000 prosthetic heart valves will be implanted every year in western countries.
Dysfunction of prosthetic heart valves is rare but can be life threatening. When it does occur, it is crucial to determine the cause as this will define what treatment is needed. The paper published provides the first recommendations on how to use multimodality imaging to detect and diagnose prosthetic heart valve complications.
When prosthetic heart valve complications are suspected, the authors recommend:
First-line imaging with 2D transthoracic echocardiography (TTE); 2D and 3D TTE and transesophageal echocardiography (TOE) for complete evaluation; Cinefluoroscopy to evaluate disc mobility and valve ring structure; Cardiac computed tomography (CT) to visualize calcification, degeneration, pannus, thrombus; Cardiac magnetic resonance imaging (CMR) to assess cardiac and valvular function; Nuclear imaging, especially when infective endocarditis is suspected.
‘In this paper we have underlined the incremental value of all imaging modalities to evaluate prosthetic heart valves,’ said Professor Lancellotti. ‘Echocardiography should be used in the first instance to detect any dysfunction. Non-echo imaging modalities can be performed afterwards if more information is needed to establish the cause and extent of complications.’
He concluded: ‘We have introduced new algorithms to help clinicians diagnose and quantify prosthetic heart valve dysfunction. They are easy to use and we hope will improve assessment and subsequent management of patients so that when complications do occur, better outcomes can be achieved.’

European Society of Cardiology http://tinyurl.com/go9gwgq

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:17Imaging assessment of prosthetic heart valves

Siemens Healthcare becomes Siemens Healthineers

, 26 August 2020/in E-News /by 3wmedia

In early May Siemens Healthcare unveiled its new brand name Siemens Healthineers. The new brand underlines Siemens Healthcare’s pioneering spirit and its engineering expertise in the healthcare industry. It is meant to describe the healthcare organization and its people – the people accompanying, serving and inspiring customers – the people behind outstanding products and solutions.
‘We have an exceptional track record of engineering and scientific excellence and are consistently at the forefront of developing innovative clinical solutions that enable providers to offer efficient, high quality patient care. Going forward as Siemens Healthineers, we will leverage this expertise to provide a wider range of customized clinical solutions that support our customers business holistically. We are confident in our capability to become their inspiring partner on our customers’ journey to success’, explained Bernd Montag, CEO of the company. ‘Our new brand is a bold signal for our ambition and expresses our identity as a people company – 45,000 employees worldwide who are passionate about empowering healthcare providers to optimally serve their patients.’
As part of its Vision 2020 strategy Siemens AG announced nearly two years ago that its healthcare business would be separately managed as a company within the company with a new organizational setup. Siemens Healthineers will continue to strengthen its leading portfolio across the medical imaging and laboratory diagnostics business while adding new offerings such as managed services, consulting and digital services as well as further technologies in the growing market for therapeutic and molecular diagnostics.

www.healthcare.siemens.com
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:24Siemens Healthcare becomes Siemens Healthineers

Antibody function may help keep tuberculosis infection under control

, 26 August 2020/in E-News /by 3wmedia

A study led by investigators from the Ragon Institute of MGH, MIT and Harvard finds evidence that antibody protection may help control infection with the bacteria that causes tuberculosis (TB). In their study the research team describes finding consistent differences in both the structure and function of antibodies targeting the TB bacteria between individuals with active TB disease and those with latent TB, which neither produces symptoms nor can be transmitted. The findings may lead to better ways of distinguishing between active and latent disease and to a more effective vaccine against a disease that kills more than 1.5 million people each year.

‘Ending tuberculosis by 2030 is one of the targets of the World Health Organization’s newly adopted Sustainable Developmental Goals,’ says Lenette Lu, MD, PhD, of the Ragon Institute and the Massachusetts General Hospital (MGH) Department of Medicine. ‘A more effective vaccine against TB could substantially contribute towards that goal, impacting the nearly one in three people worldwide who are infected and addressing the leading killer of individuals infected with HIV.’

The only currently available preventive against infection with the TB bacteria – the BCG vaccine – has been available since the 1920s; but its effectiveness against pulmonary TB, the most common form of the disease, has always been uncertain. BCG is believed to work by stimulating cellular immunity, which is carried out by specialized immune cells including T cells and the macrophages that are directly infected by TB bacteria. Previous investigations into a possible role for antibodies in the immune response to TB have had conflicting results, but the Ragon team – led by Galit Alter, PhD, of MGH Department of Medicine and Sarah Fortune, MD, of the Harvard T.H. Chan School of Public Health – used a novel approach.

In addition to binding to their target pathogens and marking them for destruction by the immune system, antibodies also directly stimulate pathogen-killing cells of the innate immune system by binding to a cell-surface protein called the Fc receptor. The Ragon team profiled TB-specific antibodies from 22 individuals with latent TB and 20 with active TB for 70 different features associated with Fc-mediated antibody function. They first identified nine characteristics that differentiated between antibodies of the two groups of participants, and further investigation identified the biomarker that best distinguished between them.

A key regulator of Fc-mediated immune function is the addition to antibodies of compounds called glycans, made up of sugar molecules; and distinct differences in glycosylation patterns were found to clearly distinguish latent TB antibodies from active TB antibodies. To confirm these results in the initial group of participants, who were from South Africa, the team conducted a similar analysis of antibodies from 20 individuals from Texas and Mexico – half with latent and half with active TB – and had the same results. Further experiments revealed that application of latent TB antibodies to TB-infected human macrophages not only increased the activation of several antimicrobial processes but also reduced the survival of the TB bacteria.

Co-lead author Amy Chung, PhD, now at the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia – a joint venture between The University of Melbourne and The Royal Melbourne Hospital – explains, ‘This is a completely new area of immune research in tuberculosis, since these antibodies don’t just recognize the infection, they also recruit immune cells to target it. People with latent infection have inactive disease for a reason, and if antibodies are playing a role in controlling the infection, the mechanism they use could be harnessed for future vaccine development.’

Alter, an associate professor of Medicine at Harvard Medical School, adds, ‘The diagnostic potential of these findings should not be overlooked. The detection of Fc-related modifications of TB-specific antibodies could be easily translated into a rapid, inexpensive point-of-care diagnostic that could have enormous public health impact, particularly in those parts of the globe where TB is endemic.’

Massachusetts General Hospitalwww.massgeneral.org/about/pressrelease.aspx?id=1992

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:03Antibody function may help keep tuberculosis infection under control

Bone marrow lesions can help predict rapidly progressing joint disease

, 26 August 2020/in E-News /by 3wmedia

A new study from the Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, shows lesions, which can best be seen on MRI scans, could help identify individuals who are more likely to suffer from more rapidly progressing osteoarthritis.
The SEKOIA study, a major international osteoarthritis disease-modifying trial, carried out MRI scanning on the knees of 176 men and women over 50 years old. They were then followed up for an average of three years with repeated knee X-rays. Individuals with abnormalities on their MRI scans at the first appointment were compared to those without to examine the effect on disease progression.
Individuals with bone marrow lesions (BMLs) on their MRI scan were found to have osteoarthritis that progressed more rapidly than those that did not. On average, the space within the joint is lost at a rate of 0.15mm per year however the Southampton study shows that, overall, individuals with BMLs had a loss rate that was 0.10mm per year faster than those without BMLs. This may lead to earlier need for joint replacement or other intervention.
BMLs show up on MRI as regions of bone beneath the cartilage with ill-defined high signal and represent areas of bone marrow edema, fibrosis, and necrosis. The Southampton researchers believe that therapies to target these abnormalities may slow the progression of this disabling joint disease, but further work is required to examine this.

University of Southampton http://tinyurl.com/zgoujax

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:11Bone marrow lesions can help predict rapidly progressing joint disease

Study shows promise of non-drug pain management

, 26 August 2020/in E-News /by 3wmedia

It’s a Catch-22 with potentially deadly consequences: People trying to overcome addiction can’t get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.
And so their pain continues to get in the way of their addiction recovery – or they seek pain relief in the same addictive substances they’re trying to avoid.

But a new study shows the potential for patients to break out of that cycle through a non-drug approach that combines behavioural therapy and social support to help them manage their pain. The low-cost approach, grounded in psychological theories of pain, could help address the nation’s epidemic of addictions to opioid painkillers and illicit drugs.

Veterans who received this pain-focused care while also being treated for addiction found that the intensity of their pain decreased, their ability to function increased, and their alcohol use went down, compared to veterans who received a less-focused approach. However, the two groups had similar rates of drug use.

Just 10 weekly sessions of the approach, called ImPAT for Improving Pain during Addiction Treatment, had an effect that lasted up to a year in 55 veterans who took part, according to the new results published by a team from the VA Ann Arbor Healthcare System’s Center for Clinical Management Research and University of Michigan Medical School’s Addiction Center.

The researchers have already launched a follow-up study in a larger group of 480 non-veterans in a residential addiction treatment program. And the study’s authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.

Addiction treatment programs often have patients who suffer from chronic pain, but offer few options to treat them, Ilgen says.’These results highlight the need for addiction treatment programs to offer a multifaceted approach that doesn’t only address substance use but also the other factors that might be driving substance use, including pain,’ says Mark Ilgen, Ph.D., the study’s lead author and a VA and U-M psychologist specializing in addiction research. ‘We’ve shown that it’s possible to improve pain outcomes in people with addiction, and even have some spillover effects on their substance use.’

To make matters worse, ‘Past studies of psychosocial approaches for pain have often excluded people with drug or alcohol problems, addiction treatment programs do not usually have providers trained in pain care, and many pain specialists will not treat people who also have addiction. So patients are caught in the middle.’

All 129 patients in the study, most of them men in their 40s and 50s, were receiving outpatient addiction treatment in a CBT-based, non-abstinence setting at the Ann Arbor VA. Half were randomly assigned to ImPAT sessions, the other half to support groups of peers, led by a therapist, where pain and addiction could be discussed.

ImPAT combines elements of cognitive behavioural therapy with another psychosocial approach called acceptance and commitment therapy.

While the two approaches aren’t usually used together, they are often used in pain treatment settings – but those clinics and programs don’t often accept people who also acknowledge they have addiction issues. Ilgen and his colleagues hope their results will help bring the techniques into addiction treatment settings, where the cognitive behavioural therapy approach is often used.

The ImPAT technique seeks to use integrated approaches both to help patients focus less on their pain and more on other aspects of life. This includes techniques to help people adapt to their pain, find ways to distract themselves from their pain, and think of ways to function in the face of pain.

‘We want to take the focus off pain and put it onto functioning, and finding pleasurable ways to spend time,’ Ilgen says. ‘There’s also a strong link between depression and pain. Pain is responsive to mood, and mood is responsive to social support.’

University of Michigan www.uofmhealth.org/news/archive/201607/treating-pain-without-feeding-addiction-study-shows-promise

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:19Study shows promise of non-drug pain management

Study assesses performance of direct-to-consumer teledermatology services

, 26 August 2020/in E-News /by 3wmedia

A study that used fake patients to assess the performance of direct-to-consumer teledermatology websites suggests that incorrect diagnoses were made, treatment recommendations sometimes contradicted guidelines, and prescriptions frequently lacked disclosure about possible adverse effects and pregnancy risks, according to an article.
In the US, direct-to-consumer teledermatology (DTC) is rapidly expanding and large DTC services are contracting with major health plans to provide telecare. However, relatively little is known about the quality of these services.
Jack S. Resneck, Jr., M.D., of the University of California, San Francisco, and co-authors used study personnel posing as patients to submit six dermatologic cases with photographs, including neoplastic, inflammatory and infectious conditions, to regional and national DTC telemedicine websites and smartphone apps offering services to California residents. The photographs were mostly obtained from publicly available online image search engines. Study patients claimed to be uninsured and paid fees using Visa gift debit cards; no study personnel provided any false government-issued identification cards or numbers.
The authors received responses from 16 DTC websites for 62 clinical encounters over about a month from February to March 2016.
The authors report:
None of the websites asked for identification or raised concern about pseudonym use or falsified photographs.
During 68 percent of encounters, patients were assigned a clinician without any choice; 26 percent disclosed information about clinician licensure; and some used internationally based physicians without California licenses; 23 percent collected the name of an existing primary care physician and 10 percent offered to send records.
A diagnosis or a likely diagnosis was given in 77 percent of cases; prescriptions were ordered in 65 percent of these cases; and relevant adverse effects or pregnancy risks were disclosed in a minority of those.
The websites made several correct diagnoses in cases where photographs alone were adequate but when additional history was needed they often failed to ask simple, relevant questions.
Major diagnoses were missed including secondary syphilis, eczema herpeticum, gram-negative folliculitis and polycystic ovarian syndrome.
Treatments prescribed were sometimes at odds with guidelines.
A significant limitation to this study is that the authors were unable to assess whether clinicians seeing these patients in traditional in-person encounters would have performed any better.
The authors offer a series of recommended practices for DTC telemedicine websites, including obtaining proof of patient identity, collecting relevant medical history, seeking laboratory tests when an in-person physician would have relied on that information, having relationships with local physicians in all the areas where they treat patients, and creating quality assurance programmes.

JAMAhttp://tinyurl.com/hctx7t5

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:27Study assesses performance of direct-to-consumer teledermatology services

Researchers develop brain-mapping technology

, 26 August 2020/in E-News /by 3wmedia

Researchers at the University of Arizona are developing a non-invasive brain-scanning technology that could produce images far superior to those obtained with the most commonly used systems – electroencephalography and functional magnetic resonance imaging.
The technique, which incorporates sound waves to measure electrical activity in neural tissue, could improve diagnosis and treatment of many disorders, including epilepsy, Parkinson’s disease and traumatic brain injury.
Russell Witte, a UA associate professor of medical imaging, biomedical engineering and optical sciences, is principal investigator of the research project.
‘We know very little about how neurons act collectively to guide our thoughts, emotions and behaviours – or cause seizures or mood swings,’ Witte said.
‘Functional magnetic resonance imaging and electroencephalography have provided some clues. But both fMRI and EEG share a major limitation: They produce images with poor resolution,’ he said. ‘We think our new technology could overcome that limitation.’
Researchers have long known of the acoustoelectric effect, in which ultrasound energy alters a material’s physical properties like electrical conductivity.
Witte is one of the first researchers to apply the phenomenon to biomedical imaging.
He has developed a non-invasive imaging technique for detecting irregular heartbeats and is working with Tech Launch Arizona, the UA office that commercializes inventions stemming from University research, to create a startup for acoustoelectric cardiac imaging.
With the new study, Witte takes his research into new terrain: the brain.
The research team will develop and test the non-invasive technology, called acoustoelectric brain imaging, or ABI, on mammalian brains for the first time.
ABI involves applying ultrasound waves externally to the brain, where they interact with electrical currents to produce a ‘signature’ wave that is picked up by an electrode attached outside the head. ABI can better localize the source of electrical activity than EEG, because it overcomes the problem of interference from the skull, and it works much faster than fMRI, which measures metabolic activity.
‘Sensory input, thoughts and behaviours are happening so fast,’ said Cowen, a neuroscientist.
‘With speech or motor activity, many actions require split-second decisions – actually, on the scale of tens of milliseconds,’ Cowen said. ‘If a brain-imaging technology is working only in seconds – fMRI, for example, can measure brain activity once every two seconds – it may be missing some of the most important details.’
Cowen added: ‘This is a very interesting adventure we’re undertaking, because nobody knows what ABI will actually measure. Will it measure the activity of tens of thousands, or hundreds of thousands, of neurons? Will it detect the activity at a specific frequency, or at a range of frequencies?’
ABI also could provide a clearer picture of activity in structures deep in the brain, such as the amygdala and hippocampus.

University of Arizona http://tinyurl.com/zw5f6he

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:06Researchers develop brain-mapping technology

Researchers use gene therapy to extend estrogen’s protective effects on memory

, 26 August 2020/in E-News /by 3wmedia

The hormone oestrogen helps protect memory and promote a healthy brain, but this effect wanes as women age, and even estrogen replacement therapy stops working in humans after age 65. Now researchers at University of Florida Health have used gene therapy in a rat model to show that the expression of a particular receptor can reinstate lost memory function.
The scientists included Thomas C. Foster, Ph.D., a professor of neuroscience and the Evelyn F. McKnight chair for research on cognitive aging, and Linda A. Bean, Ph.D.
‘There is a window of time, starting around menopause, when initiation of hormone replacement therapy with estrogen protects the brain against injury and Alzheimer’s disease. However, this window seems to end around age 65,’ Foster said. ‘We wanted to find out what is regulating this window.’
The researchers used gene therapy to overexpress two different estrogen receptors found in the hippocampus, a part of the brain essential to memory regulation. They found that an abundance of one of these receptors, called alpha, reinstated memory in aging rats when paired with estrogen.
Estrogen helps to do this by increasing the brain’s ‘plasticity,’ which is the ability to form and maintain connections between brain cells as things are learned. As plasticity declines, so do the number of connections in the brain, and certain types of memories begin to fade. Without the protective effect of estrogen, women may lose brain plasticity and start forgetting things more often. The loss of estrogen’s protective effects may explain why women are more likely than men to develop dysfunctional memory problems such as Alzheimer’s disease.
The researchers looked at the effects on memory in six groups, which received gene therapy for expression of the alpha receptor, the beta receptor or a control gene. The three different gene therapy groups then received estrogen or a placebo for the next several weeks, until memory testing and examination of brain plasticity. The project involved 72 animals. Only the group with gene therapy for the alpha receptor plus estrogen showed any beneficial effects on memory and increased brain plasticity markers.
‘In the short term, this finding helps us understand how estrogen rescues memory and keeps the brain young and plastic,’ Foster said. ‘In the long term, this finding may eventually allow us to bypass estrogen and target the receptor or brain plasticity mechanisms directly.’

University of Florida Health http://tinyurl.com/qbkrmz9

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:38:032020-08-26 14:38:14Researchers use gene therapy to extend estrogen’s protective effects on memory
Page 167 of 231«‹165166167168169›»

Latest issue of International Hospital

April 2024

4 July 2025

Everdrone expands world-first medical emergency drone network in Sweden

4 July 2025

Wireless implant breakthrough offers personalised chronic pain relief

3 July 2025

EEG-powered brain computer interface enables finger-level robotic hand control

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription